This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
TG4010
Accession Number
DB06584
Type
Biotech
Groups
Investigational
Biologic Classification
Vaccines
Other vaccines
Description

A bivalent cancer vaccine comprised of a modified vaccinia virus Ankara (MVA) strain encoding human mucin 1 (MUC1) and interleukin-2 (IL-2) with potential immunostimulating and antineoplastic activities. Originally developed for the eradication of smallpox, MVA is a highly attenuated and replication-defective strain incapable of virion assembly and exerts potent immunostimulatory activity against antigens. Vaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in tumor cell lysis. Expression of IL-2 augments the specific CTL response against MUC1 expressing cells. 1

Synonyms
  • MVA-Muc1-IL2
External IDs
TG 4010 / TG4010
Categories
UNII
Not Available
CAS number
350485-85-7

Pharmacology

Indication

Investigated for use/treatment in breast cancer, renal cell carcinoma, prostate cancer, and lung cancer.

Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UMucin-1Not AvailableHumans
UInterleukin-2Not AvailableHumans
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of TG4010 can be decreased when used in combination with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of TG4010 can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of TG4010 can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of TG4010 can be decreased when used in combination with Abetimus.
ActeosideThe therapeutic efficacy of TG4010 can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of TG4010 can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of TG4010 can be decreased when used in combination with Afelimomab.
AldesleukinThe therapeutic efficacy of TG4010 can be decreased when used in combination with Aldesleukin.
AldosteroneThe therapeutic efficacy of TG4010 can be decreased when used in combination with Aldosterone.
AlefaceptThe therapeutic efficacy of TG4010 can be decreased when used in combination with Alefacept.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. NCI Drug Dictionary: MVA-MUC1-IL2 vaccine [Link]
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
2Active Not RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage I Non-Small Cell Lung Cancer / Stage II Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIb Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentProstatic Neoplasms1
2, 3CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2, 3TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Transcription cofactor activity
Specific Function
The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.The ...
Gene Name
MUC1
Uniprot ID
P15941
Uniprot Name
Mucin-1
Molecular Weight
122100.89 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Kinase activator activity
Specific Function
Produced by T-cells in response to antigenic or mitogenic stimulation, this protein is required for T-cell proliferation and other activities crucial to regulation of the immune response. Can stimu...
Gene Name
IL2
Uniprot ID
P60568
Uniprot Name
Interleukin-2
Molecular Weight
17627.52 Da

Drug created on March 19, 2008 10:38 / Updated on June 12, 2020 10:52

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates